All In Biotech

Drug Trial Radar · NCT06144710

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Characteristics of SG301 SC Injection in Single-dose Healthy Subjects and Multiple-dose Systemic Lupus Erythematosus (SLE) Subjects

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Nov 10, 2023

Primary completion

Jan 7, 2026

Study completion Jan 7, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • SG301 SC InjectionDrug

    Subcutaneous injection every two weeks

  • SG301 SC PlaceboDrug

    Subcutaneous injection every two weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events(Part A and Part B)Time frame: From baseline through the end of study. Part A: Average 2 months per subject, Part B: Average 5 months per subject.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Shandong University Qilu Hospital

    Jinan, Shandong, China

  • Jining First People's Hospital

    Jining, Shandong, China

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.